### PRINTO PROJECTS

MTX JIA JDM trial JSLE trial

Argentina	27		
Australia			
Austria			
Belaium			
Brasil	32		
Bulgaria	20		
Canada			
Chile	18		
Costa Rica			
Croatia	4		
Cuba			
Czech Republic	5		
Denmark	2		
Finland			
France	9		
Georgia	2		
Germany	36		
Greece	17		
Hungary	1		
India	9		
Israel	8		
Italy	31	1	
Korea			
Kuwait	2		
Latvia	20		
Mexico	2		
Netherlands	46		
Norway			
Poland	1		
Portugal	3		
Russia	2		
Saudi Arabia			
Serbia	16		
Singapore			
Slovakia	4		
Slovenia			
Spain	16		
Sweden			
Switzerland	4		
Turkey	2		
Un. Kinadom	15		
USA			
Total	354	1	0

"Paediatric Rheumatology INternational



# PRINTO"

IRCCS

**JUNE 2006** 

## Paediatric Rheumatology InterNational Trials Organisation (PRINTO)



### ADVISORY COUNCIL

### Chairman

Alberto Martini, MD, Prof - Genova, Italy Counsellors

Boel Andersson Gäre, MD, PhD - Jönköping, Sweden Wietse Kuis, MD, PhD, Prof - Utrecht, Netherlands Anne-Marie Prieur, MD - Paris, France Patricia Woo, MD, FRCP, PhD, Prof-London, Un Kingdom Senior Scientist

Nicola Ruperto, MD, MPH - Genova, Italy

IRCCS G. Gaslini

Pediatria II - PRINTO

Largo Gaslini, 5

16147 Genova, ITALY

Tel: +39-010-38-28-54 or +39-010-39-34-25

Fax +39-010-39-33-24 or +39-010-39-36-19

E-mail: printo@ospedale-gaslini.ge.it

Web: www.printo.it OR www.pediatric-rheumatology.printo.it

Supported by European Union: grant no AML/B7-311/97/0666/II-0246-FI 2003-2006



### PReS Congress 2006 Amsterdam Netherlands

Thursday June 22 (9.00-10.00)
Park Foyer

Agenda for the annual PRINTO workshop

- Update on PRINTO activities (A. Martini)
- NEW PRINTO Projects: trials in juvenile systemic lupus erythematosus (JSLE) nephritis and juvenile dermatomyositis (JDM) (N. Ruperto)
- Update on PRINTO projects (N. Ruperto)

### JSLE and JDM trials:

- JDM trial:
  - prednisone (PDN) versus
  - PDN plus (MTX) versus
  - PDN plus Cyclosporine A.
- JSLE class III-IV nephritis trial:
  - PDN and oral cyclophosphamide (CYC) versus
  - PDN and intermediate dose iv CYC verus
  - PDN and high dose iv CYC
     all followed by azathioprine

### The first JDM patient has been enrolled

IMPORTANT thanks to a grant from the Italian Agency for Drug Evaluation (AIFA), the Myositis Association and other source of funding PRINTO is now able to provide 300 euro for every patient enrolled in the trial. For interested centres more information will be presented at the PRINTO workshop and are available at

www.printo.it in the member area

MTX withdrawal study: to determine if the time to discontinuation of MTX (6 versus 12 months) in JIA, after clinical remission, influences the time to relapse. A total of 354patients have been enrolled (original sample 200).

Enrollment is now over.

# JSLE and JDM disease activity and damage study.

The pediatric JSLE definition definition of improvement has been officially endorsed by the American College of Rheumatology (see paper) as:

The PRINTO/ACR Provisional Criteria for the Evaluation of Response to Therapy in JSLE.

IMPORTANT we are missing just the final 5% of data for the damage assessment phase. Data collection will continue until September 2006:

- Visit 3 at least 1 year after baseline
- Visit 4 at least 2 years after baseline Please remember to send the case report forms (complete visits) by fax or mail.

Website for families final version in more than 50 languages available at www.pediatric-rheumatology.printo.it

At the end of June 2006 reached a new hit with 5,000 people per day (150.000 per month), from 130 different countries!.

Membership: 377 effective members in 208 centres from 46 countries.

### Recent PRINTO publications

To see the PRINTO papers and ask for reprints go at www.printo.it and click on papers.

•Ruperto N, Ravelli A, Cuttica R, Espada G, Ozen S, Porras O, Sztajnbok F, Falcini F, Kasapcopur O, Venning H, Bica B, Merino R, Coto V, Ros J, Susic G, Gamir ML, Minden K, See Y, Uziel Y, Mukamel M, Riley P, Zulian F, Olivieri AN, Cimaz R, Girschick H, Rumba I, Cavuto S, Pistorio A, Lovell DJ, Martini A, for PRINTO and PRCSG. The PRINTO criteria for the evaluation of response to therapy in juvenile

systemic lupus erythematosus. Prospective va-

lidation of the core set. Arthritis Rheum 20-

05;52(9):2854-2864.

•Ruperto N, Ravelli A, Oliveira S, Alessio M, Mihaylova D, Pasic S, Cortis E, Apaz M, Burgos-Vargas R, Kanakoudi-Tsakalidou F, Norambuena X, Corona F, Gerloni V, Hagelberg S, Aggarwal A, Dolezalova P, Magalhaes Saad C, Bae SC, Vesely R, Avcin T, Foster H, Duarte C, Herlin T, Horneff G, Lepore L, Van Rossum M, Trail L, Pistorio A, Andersson-Gäre B, Giannini EH, Martini A, for PRINTO and PRCSG. The PRINTO/ACR provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus. Prospective validation of the definition of improvement. Arthritis Rheum 2006;55(3):355-363